ClinicalTrials.gg
RecruitingNCT07596381Updated Nov 13, 2026

FAK Inhibitor in Patients With Advanced Solid Tumors

A Phase 1 interventional study of IN10028 in Advanced Solid Tumors, sponsored by InxMed (Shanghai) Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by InxMed (Shanghai) Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 13, 2026Now RecruitingSite recruiting status changed+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
75
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

This is A Phase I/Ib Study,aimed to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Efficacy of Focal Adhesion Kinase Inhibitor IN10028 as Monotherapy and Combination Therapy in Patients with Advanced Solid Tumors.

Read the detailed description

Same-target drugs of IN10028 include Ifebemtinib (a first-generation focal adhesion kinase [FAK] inhibitor), defactinib (Verastem Oncology), VS-4748 (Verastem Oncology), and GSK2256098 (GlaxoSmithKline [GSK] plc). IN10028 is a potent, highly selective, orally available second-generation focal adhesion kinase (FAK, also known as protein tyrosine kinase 2 [PTK2]) inhibitor . It binds to the kinase domain of FAK to block activation of downstream oncogenic PI3K/AKT and RAS/MAPK signaling pathways, thus suppressing tumor cell proliferation, inducing apoptosis, and markedly attenuating tumor cell migration and invasion.Based on the clinically validated target value of the first-generation FAK inhibitor Ifebemtinib (Ifebe, IN10018, original development code BI 853520) and its associated limitation of proteinuria, IN10028 has been specifically optimized to achieve more potent target inhibition and a potentially superior safety profile. Given the well-established clinical value of the FAK target and successful clinical experience with other same-target agents,there is a robust, well-supported clinical development rationale for IN10028.

A Phase I/Ib clinical trial is planned by the sponsor to evaluate the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of FAK inhibitor IN10028 as monotherapy and in combination with other anticancer agents in patients with advanced solid tumors.

02

Conditions studied

  • Advanced Solid Tumors
03

In context

Lead sponsor

InxMed (Shanghai) Co., Ltd. is the lead sponsor of 13 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to understand and voluntarily sign the written Form (ICF), which must be signed prior to conducting the study-specific procedures required by the trial.
  • At the time of signing the ICF, subjects are aged 18 to 75 years, inclusive, male and female.
  • Subjects must have a or cytologically confirmed diagnosis of advanced or malignant solid tumor.Monotherapy dose-escalation and dose expansion: Patients with solid tumors who failed prior standard systemic therapy, have no standard treatment options, or are intolerant to standard regimens.
  • Prior systemic antitumor therapy must be completed at least 3 weeks before the first study drug treatment; prior small molecule TKIs or oral fluoropyrimidines require a minimum 2-week .
  • Subjects must have at least one measurable tumor lesion per v1.1. Previously irradiated lesions should not be selected as target lesions, unless such irradiated lesion is the only and has documented radiological disease progression, and may then be selected as a target lesion.
  • (ECOG) performance status score of 0 or 1.
  • Subjects have an estimated expected survival time of at least 3 months.
  • Has adequate organ function.
  • Urine protein negative or trace (±); or urine protein 1+, but urine protein to creatinine ratio (UPCR) of random morning urine \< 0.5, or 24-hour urine protein quantitation \< 0.5 g/24 h.
  • Female subjects of must have a negative serum pregnancy test and agree to use effective during the study drug treatment period and for 120 days after the last dose of study drug administration. Male subjects with female partners of childbearing potential must agree to use effective contraception during the study drug treatment period and for 120 days after the last dose of study drug administration. In this protocol, a woman of childbearing potential is defined as a sexually mature female.

Exclusion criteria

Exclusion Criteria:

  • Subjects unable to receive oral administration or with conditions that severely affect drug digestion and absorption (e.g., subtotal gastrectomy or duodenectomy, severe sinus tract affecting digestion and absorption, and other related diseases.
  • Subjects with known central nervous system (CNS) , excluding those with asymptomatic or asymptomatic brain metastases following prior treatment, provided that the lesions have been confirmed to be stable for more than 3 months by computed tomography (CT) or magnetic resonance imaging (MRI), and no therapy has been required for at least 4 weeks.
  • Subjects with known to any components of the study drug or its analogues.
  • Subjects with prior treatment of focal adhesion kinase inhibitors (FAKi).
  • Subjects with a history of any other within 5 years prior to screening, excluding cured cervical carcinoma in situ and completely resected basal cell carcinoma of the skin.
  • Subjects with uncontrolled cardiac clinical symptoms or diseases, including:(1) Heart failure classified as (NYHA) Class Ⅱ or above; (2) unstableangina; (3) Myocardial infarction within the past 1 year;(4) supraventricular or ventricular arrhythmia requiring treatment or intervention; (5) interval (QTc) > 450 ms in males and QTc > 470 ms in females. The QTc interval is calculated using Fridericia's correction formula: QTcF = QT/(RR\^0.33); (6) (LVEF) \< 50%.
  • Subjects with known hereditary or acquired bleeding and thrombotic predispositions (e.g., hemophilia, coagulation disorders, thrombocytopenia, etc.)
  • Subjects with an active infection within 4 weeks prior to enrollment, or those with other chronic medical conditions deemed unsuitable for study participation by the Investigator.
  • Subjects with congenital or acquired immunodeficiency disorders (e.g., [HIV] infection), or those with a history of organ transplantation.
  • surface antigen (HBsAg) positive with hepatitis B virus DNA (HBV DNA) ≥ 2500 copies/mL (or 500 IU/mL); or positive for virus RNA (HCV RNA).
  • Have received a within 30 days prior to the first dose of administration.
  • Women of who are pregnant-planning or lactating.
  • Subjects who are inability to comply with protocol requirements or who is otherwise considered unsuitable for study participation by the investigator's judgment.
  • Subjects receiving concomitant intravenous or oral medications that affect CYP isoenzymes (strong inducers or strong inhibitors of ), or who have used such medications within at least 1 week prior to the first dose of administration.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    IN10028

    The monotherapy dose-escalation will adopt an accelerated titration design combined with the conventional 3+3 dose-escalation method. The starting dose of IN10028 is 25 mg, with a total of 5 planned dose cohorts: 25 mg, 50 mg, 100 mg, 200 mg and 300 mg, administered orally once daily (QD) continuously.The DLT observation period is 14 days at the 25 mg dose level, and 21 days at the 50 mg, 100 mg, 200 mg and 300 mg dose levels, respectively.

    Drug: IN10028

Interventions

  • DrugIN10028

    The starting dose of IN10028 is 25 mg, with a total of 5 planned dose cohorts: 25 mg, 50 mg, 100 mg, 200 mg and 300 mg, administered orally once daily (QD) continuously with a cycle of 21 days.

06

What researchers measure

Primary outcomes

  1. To explore the incidence of dose-limiting toxicities (DLTs) of IN10028, identify the maximum tolerated dose (MTD), and determine the recommended phase 2 dose (RP2D).

    To evaluate the safety and tolerability of IN10028 in patients with advanced malignant solid tumors, characterize the incidence of dose limiting toxicities (DLTs), identify the maximum tolerated dose (MTD), and determine the recommended phase 2 dose (RP2D).

    Time frame: Approximately 6 months

Secondary outcomes

  1. PK:AUC0-24h of IN10028

    To evaluate area under the plasma concentration-time curve from 0 to 24 hours (AUC0-24h) profile following single- and multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  2. PK: AUC0-t of IN10028

    To evaluate the area under the plasma concentration-time curve from 0 to the last measurable time point (AUC₀-t) profile following single- and multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  3. PK: AUC0-∞ of IN10028

    To evaluate area under the plasma concentration-time curve from time 0 to infinity (AUC₀-∞) profile following single-dose and multiple-dose dosing of IN10028.

    Time frame: Approximately 6 months

  4. PK: AUCextrap(%) of IN10028

    To evaluate percent of aucinf attributed to extrapolation (AUCextrap(%) )profile following single-dose and multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  5. PK: Cmax of IN10028

    Maximum plasma concentration (Cmax) profile following single-dose administration of IN10028.

    Time frame: Approximately 6 months

  6. PK: Tmax of IN10028

    Time to reach maximum plasma concentration (Tmax) profile following single-dose administration of IN10028.

    Time frame: Approximately 6 months

  7. PK: t1/2 of IN10028

    Elimination half-life (t1/2) profile following single-dose and multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  8. PK: λz of IN10028

    Terminal elimination rate constant (λz) profile following single-dose and multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  9. PK: Vz/F of IN10028

    Apparent volume of distribution during the terminal phase(Vz/F) following single-dose administration of IN10028.

    Time frame: Approximately 6 months

  10. PK: CL/F of IN10028

    Apparent total clearance during the elimination phase(CL/F) following single-dose administration of IN10028.

    Time frame: Approximately 6 months

  11. PK: Cmax,ss of IN10028

    To evaluate the maximum steady-state plasma drug concentration(Cmax,ss)following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  12. PK: Cmin,ss of IN10028

    To evaluate the minimum steady-state plasma drug concentration(Cmin,ss)following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  13. PK: Cav,ss of IN10028

    To evaluate the average steady-state plasma drug concentration(Cav,ss)following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  14. PK: AUC0-tau of IN10028

    To evaluate the time-concentration curve from time zero to the end of the dosing interval (tau)(AUC0-tau)following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  15. PK: CLss/F of IN10028

    To evaluate the apparent total clearance at steady state (CLss/F) following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  16. PK: Vz,ss/F of IN10028

    To evaluate the apparent steady-state volume of distribution during the terminal phase (Vz,ss/F) following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  17. PK: Flu% of IN10028

    To evaluate the percentage of fluctuation at steady state (Flu%) following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  18. PK: Rac of IN10028

    To evaluate the percent fluctuation at steady state (Rac) following the multiple-dose administration of IN10028.

    Time frame: Approximately 6 months

  19. To evaluate the rate of Objective Response Rate (ORR) of IN10028 in solid tumors.

    Defined as the proportion of subjects with complete response (CR) or partial response (PR).

    Time frame: Approximately 1 year

  20. To evaluate the time of Duration of Response (DoR) of IN10028 in solid tumors.

    Defined as the time from start of the first documentation of CR or PR to the first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: Approximately 1 year

  21. To evaluate the rate of Disease Control Rate (DCR) of IN10028 in solid tumors.

    Defined as the proportion of patients with CR, PR, or stable disease (SD).

    Time frame: Approximately 1 year

  22. To evaluate the Time To Response (TTR) of IN10028 in solid tumors.

    To preliminarily evaluate the antitumor activity of IN10028 time to response (TTR).

    Time frame: Approximately 1 year

  23. To evaluate the duration of Progression-free Survival (PFS) of IN10028 in solid tumors.

    Defined as the time from the first dose of study treatment to first documentation of disease progression or to death due to any cause, whichever comes first.

    Time frame: Approximately 1 year

  24. To Evaluate the duration of Overall survival (OS) of IN10028 in solid tumors.

    Defined as the time from the first dose of study treatment to the date of death due to any cause.

    Time frame: Approximately 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2026 (actual). Primary completion is estimated for Sep 2027, 16 months after the start.

Primary completion moved once since we started tracking on Sep 25, 2026: Feb 2027 → Sep 2027, on Nov 13, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 1, 2026
First posted
May 19, 2026
StartActual
May 11, 2026
Primary completionEst.
Sep 30, 2027was Feb 2027
CompletionEst.
Feb 28, 2028
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
Zhejiang Cancer Hospital is now Recruiting
Nov 13, 2026
Start date
May 30, 2026→May 11, 2026 (actual)
Nov 13, 2026
Primary completion
Feb 28, 2027→Sep 30, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    Zhejiang Cancer Hospital is now Recruiting
    Start date May 30, 2026→May 11, 2026 (now actual)
    Primary completion Feb 28, 2027→Sep 30, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07596381
Lead sponsor
InxMed (Shanghai) Co., Ltd.
Collaborators
InxMed (Nanjing) Co., Ltd.
Responsible party
Sponsor
First posted
May 19, 2026
Start date
May 11, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Feb 28, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

xiaofang liu Project Manager, Bachelor
Contact
xiaofang.liu@inxmed.com
86+13308303078
jack zhang Clinical Trial Manager, bachelor
Contact
jack.zhang@inxmed.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion